Analgesic alcohol "specific warning" format may disrupt information flow -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
ANALGESIC ALCOHOL "SPECIFIC WARNING" FORMAT MAY DISRUPT FLOW of label information to consumers, the Nonprescription Drug Manufacturers Association says in Jan. 28 comments on FDA's proposed alcohol warnings for analgesics. Echoing its previous comments on FDA's proposed overall OTC drug labeling revision regs, NDMA objects to the requirement for "specific" warnings, such as the Reye syndrome warning, on OTC product labeling. "We continue to believe that this aspect of FDA's proposal may cause disruption of the logical flow of warnings information, depending on the OTC medicine, and consumer confusion as to the relative importance (or unimportance) of the warnings," NDMA states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning